Articles citing this paper
Exploring the implications of a fixed budget for new medicines: a study of reimbursement of new medicines in Australia and New Zealand
Colman Taylor A B C E and Michael Wonder D
+ Author Affiliations
- Author Affiliations
A The George Institute for Global Health, PO Box M201 Missenden Road, Camperdown, NSW 2050, Australia.
B Sydney Medical School, Edward Ford Building A27, The University of Sydney, NSW 2006, Australia.
C Optum, Level 1, 370 Norton Street, Lilyfield, NSW 2040, Australia.
D Wonder Drug Consulting Pty Ltd, PO Box 470, Cronulla, NSW 2230, Australia. Email: wonderdrug@optusnet.com.au
E Corresponding author. Email: ctaylor@georgeinstitute.org.au
Australian Health Review 39(4) 455-461 https://doi.org/10.1071/AH14122
Submitted: 25 July 2014 Accepted: 30 January 2015 Published: 10 March 2015
7 articles found in Crossref database.
Leading Causes of Mortality and Prescription Drug Coverage in Canada and New Zealand
Rawson Nigel S. B.
Frontiers in Public Health. 2020 8
Decision-making on listing new medicines for public funding in New Zealand: the case of ‘new’ type 2 diabetes medications
Sarkisova Farzana,
Lessing Charon, Stretton Caroline
Journal of Primary Health Care. 2022 14(1). p.13
Medicines access programs to cancer medicines in Australia and New Zealand: An exploratory study
Grover Piyush,
Babar Zaheer-Ud-Din,
Oehmen Raoul, Vitry Agnes
Health Policy. 2018 122(3). p.243
Evaluating New Zealanders’ Values for Drug Coverage Decision Making: Trade-Offs between Treatments for Rare and Common Conditions
Yamoah Linda,
Dragojlovic Nick,
Smith Alesha,
Lynd Larry D., Marra Carlo A.
PharmacoEconomics. 2021 39(1). p.109
Patient access to medicines in two countries with similar health systems and differing medicines policies: Implications from a comprehensive literature review
Babar Zaheer- Ud-Din,
Gammie Todd,
Seyfoddin Ali,
Hasan Syed Shahzad, Curley Louise E.
Research in Social and Administrative Pharmacy. 2019 15(3). p.231
Differential multiple sclerosis treatment allocation between Australia and New Zealand associated with clinical outcomes but not mood or quality of life
Phyo Aung Zaw Zaw,
Jelinek George A.,
Brown Chelsea R.,
O'Kearney Emily,
Neate Sandra L.,
De Livera Alysha M,
Taylor Keryn L.,
Bevens William,
Simpson, Steve, Weiland Tracey J.
Multiple Sclerosis and Related Disorders. 2019 30 p.25
Regulatory approval and public drug plan listing of new drugs for rare disorders in Canada and New Zealand
Rawson Nigel S. B.
Journal of Population Therapeutics & Clinical Pharmacology. 2020 27(2). p.e69
